Authored by James Sheppard
The Netherlands and US based biotech company Harbour Antibodies announced that they had received $3.3m to accelerate the development and discovery of novel antibody based human therapies.
The funding round was led by Atlas Ventures. In the round a new CEO was also appointed, BJ Bormann, after moving from her previous position at Boehringer Ingelheim where she was SVP Business Development & Licensing. As part of the deal Atlas Venture’s Peter Barrett will join the board of directors.
Harbour Antibodies is currently developing transgenic mouse lines that are used to develop human antibodies which allow researchers to accelerate drug development while reducing costs. Harbour’s H2L2 mice are developed for conventional human antibodies while its HCAb mice are producing heavy chain only antibodies. Both lines are currently available for licensing. The announced financing will be used to continue the development of these models as well as looking at novel mice models.
Peter Barrett, Partner at Atlas Ventures, said ‘The Harbour team has developed technology that is nothing short of a major bioengineering feat. Making these mice available to any research organisation, public or private, will help to accelerate the discovery of promising new human antibody biopharmaceuticals.’ Professor Frank Grosveld, CSO and co-founder of Harbour went on to say ‘There is a need for new transgenic mouse platforms to meet the continuing demand for human antibody therapies. The Harbour HL2 mice meet the need for normal human antibodies and the HCAb mice provide a novel approach to generate next generation antibodies including bispecifics.’